Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
11%(1 trials)

Phase Distribution

Ph phase_1
2
20%
Ph phase_2
7
70%
Ph phase_3
1
10%

Phase Distribution

2

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
7(70.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 27 (70.0%)
Phase 31 (10.0%)

Trials by Status

withdrawn110%
completed990%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00041314
completedphase_2

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

NCT00283803
completedphase_2

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00041054
completedphase_2

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00052845
withdrawnphase_2

Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis

NCT00026468
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00041314Phase 2

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed
NCT00283803Phase 2

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Completed
NCT00041054Phase 2

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed
NCT00052845Phase 2

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Completed
NCT00026468Phase 2

Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis

Withdrawn
NCT00078910Phase 2

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

Completed
NCT00037609Phase 1

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Completed
NCT00085826Phase 3

A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

Completed
NCT00072618Phase 1

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

Completed
NCT00166426Phase 2

Exisulind Versus Placebo After Surgical Removal of the Prostate

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10